
## Samuele Massarut

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9439566/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The SCARE 2020 Guideline: Updating Consensus Surgical CAse REport (SCARE) Guidelines. International Journal of Surgery, 2020, 84, 226-230.	2.7	5,005
2	The SCARE Statement: Consensus-based surgical case report guidelines. International Journal of Surgery, 2016, 34, 180-186.	2.7	1,585
3	STROCSS 2019 Guideline: Strengthening the reporting of cohort studies in surgery. International Journal of Surgery, 2019, 72, 156-165.	2.7	1,248
4	Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial. Lancet Oncology, The, 2013, 14, 297-305.	10.7	998
5	Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet, The, 2014, 383, 603-613.	13.7	740
6	The STROCSS statement: Strengthening the Reporting of Cohort Studies in Surgery. International Journal of Surgery, 2017, 46, 198-202.	2.7	727
7	Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A) Tj ETQq1 91-102.	l 0.784314 i 13.7	gBT /Overloc 677
8	The PROCESS 2020 Guideline: Updating Consensus Preferred Reporting Of CasE Series in Surgery (PROCESS) Guidelines. International Journal of Surgery, 2020, 84, 231-235.	2.7	583
9	Preferred reporting of case series in surgery; the PROCESS guidelines. International Journal of Surgery, 2016, 36, 319-323.	2.7	351
10	Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncology, The, 2018, 19, 1385-1393.	10.7	342
11	Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the international Breast Cancer Study Group (IBCSG) trial VI. European Journal of Cancer, 1998, 34, 632-640.	2.8	206
12	Targeted Intraoperative Radiotherapy Impairs the Stimulation of Breast Cancer Cell Proliferation and Invasion Caused by Surgical Wounding. Clinical Cancer Research, 2008, 14, 1325-1332.	7.0	200
13	Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ, The, 2020, 370, m2836.	6.0	165
14	Intraoperative radiotherapy for breast cancer. Lancet Oncology, The, 2004, 5, 165-173.	10.7	160
15	A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-1± in metastatic melanoma patients. Cancer Immunology, Immunotherapy, 2006, 55, 958-968.	4.2	134
16	TARGeted Intraoperative radiotherapy (TARGIT): An innovative approach to partial-breast irradiation. Seminars in Radiation Oncology, 2005, 15, 84-91.	2.2	130
17	Long-Term Results of Targeted Intraoperative Radiotherapy (Targit) Boost During Breast-Conserving Surgery. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1091-1097.	0.8	125
18	Effect of Delayed Targeted Intraoperative Radiotherapy vs Whole-Breast Radiotherapy on Local Recurrence and Survival. JAMA Oncology, 2020, 6, e200249.	7.1	83

SAMUELE MASSARUT

#	Article	IF	CITATIONS
19	Targeted intraoperative radiotherapy (TARGIT) yields very low recurrence rates when given as a boost. International Journal of Radiation Oncology Biology Physics, 2006, 66, 1335-1338.	0.8	79
20	Reduced Mortality With Partial-Breast Irradiation for Early Breast Cancer: AÂMeta-Analysis of Randomized Trials. International Journal of Radiation Oncology Biology Physics, 2016, 96, 259-265.	0.8	79
21	Rethinking neoadjuvant chemotherapy for breast cancer. BMJ: British Medical Journal, 2018, 360, j5913.	2.3	73
22	Improved Natural Killer cell activity and retained anti-tumor CD8+ T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy. Journal of Translational Medicine, 2015, 13, 204.	4.4	64
23	Radiotherapy-induced miR-223 prevents relapse of breast cancer by targeting the EGF pathway. Oncogene, 2016, 35, 4914-4926.	5.9	63
24	Pride, Prejudice, or Science: Attitudes Towards the Results of the TARGIT-A Trial of Targeted Intraoperative Radiation Therapy for Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 92, 491-497.	0.8	60
25	Surgery-induced wound response promotes stem-like and tumor-initiating features of breast cancer cells, <i>via</i> STAT3 signaling. Oncotarget, 2014, 5, 6267-6279.	1.8	57
26	Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients. Journal of Translational Medicine, 2011, 9, 78.	4.4	52
27	<i>In vivo</i> dosimetry with radiochromic films in lowâ€voltage intraoperative radiotherapy of the breast. Medical Physics, 2012, 39, 2359-2368.	3.0	50
28	Environmental and social benefits of the targeted intraoperative radiotherapy for breast cancer: data from UK TARGIT-A trial centres and two UK NHS hospitals offering TARGIT IORT. BMJ Open, 2016, 6, e010703.	1.9	50
29	Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients. Journal of Translational Medicine, 2012, 10, 185.	4.4	49
30	Downregulation of miR-223 Expression Is an Early Event during Mammary Transformation and Confers Resistance to CDK4/6 Inhibitors in Luminal Breast Cancer. Cancer Research, 2020, 80, 1064-1077.	0.9	49
31	The largest multicentre data collection on prepectoral breast reconstruction: The iBAG study. Journal of Surgical Oncology, 2020, 122, 848-860.	1.7	48
32	Quality of Life in Women Diagnosed with Breast Cancer after a 12-Month Treatment of Lifestyle Modifications. Nutrients, 2021, 13, 136.	4.1	43
33	Mediterranean diet and quality of life in women treated for breast cancer: A baseline analysis of DEDiCa multicentre trial. PLoS ONE, 2020, 15, e0239803.	2.5	42
34	Immunohistochemical evaluation of multiple biological markers in ductal carcinoma in situ of the breast. European Journal of Cancer, 1996, 32, 1148-1155.	2.8	34
35	Low glycemic index diet, exercise and vitamin D to reduce breast cancer recurrence (DEDiCa): design of a clinical trial. BMC Cancer, 2017, 17, 69.	2.6	31
36	New clinical and biological insights from the international TARGIT-A randomised trial of targeted intraoperative radiotherapy during lumpectomy for breast cancer. British Journal of Cancer, 2021, 125, 380-389.	6.4	30

SAMUELE MASSARUT

#	Article	IF	CITATIONS
37	p70S6 kinase mediates breast cancer cell survival in response to surgical wound fluid stimulation. Molecular Oncology, 2014, 8, 766-780.	4.6	28
38	The use of thallium-201 in the preoperative detection of breast cancer: an adjunct to mammography and ultrasonography. European Journal of Nuclear Medicine and Molecular Imaging, 1995, 22, 1110-1117.	2.1	27
39	Pigmented mammary Paget's disease mimicking melanoma. Melanoma Research, 2004, 14, S13-S15.	1.2	24
40	Role of Glucocorticoids in Breast Cancer. Current Pharmaceutical Design, 2010, 16, 3593-3600.	1.9	22
41	Electron Density and Biologically Effective Dose (BED) Radiomics-Based Machine Learning Models to Predict Late Radiation-Induced Subcutaneous Fibrosis. Frontiers in Oncology, 2020, 10, 490.	2.8	20
42	Breast metastasis of primary colon cancer with micrometastasis in the axillary sentinel node: A metastasis that metastasized?. Diagnostic Pathology, 2011, 6, 45.	2.0	19
43	Inhibition of breast cancer local relapse by targeting p70S6 kinase activity. Journal of Molecular Cell Biology, 2013, 5, 428-431.	3.3	19
44	Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor. Annals of Oncology, 2005, 16, 716-725.	1.2	18
45	Beneficial Effects of Intraoperative Radiotherapy on Tumor Microenvironment Could Improve Outcomes (Int J Radiat Oncol Biol Phys 2008;72:1575–1581). International Journal of Radiation Oncology Biology Physics, 2009, 74, 976.	0.8	17
46	Locoregional Failure in Early-Stage Breast Cancer Patients Treated With Radical Mastectomy and Adjuvant Systemic Therapy: Which Patients Benefit From Postmastectomy Irradiation?. International Journal of Radiation Oncology Biology Physics, 2012, 83, e153-e157.	0.8	17
47	Breast Angiosarcoma after Conservative Surgery, Radiotherapy and Prosthesis Implant. Acta Oncológica, 1998, 37, 209-211.	1.8	16
48	<scp><i>CDKN1B</i></scp> mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancer. Journal of Pathology, 2021, 253, 234-245.	4.5	12
49	Pitfalls in the dermoscopic diagnosis of amelanotic melanoma. Journal of the American Academy of Dermatology, 2010, 62, 893-894.	1.2	11
50	Prediction of skin dose in lowâ€ <scp>kV</scp> intraoperative radiotherapy using machine learning models trained on results of <i>inÂvivo</i> dosimetry. Medical Physics, 2019, 46, 1447-1454.	3.0	11
51	Intraoperative radiotherapy for breast cancer: powerful evidence to change practice. Nature Reviews Clinical Oncology, 2021, 18, 187-188.	27.6	11
52	Seriâ"¢: A surgical scaffold for breast reconstruction or for bacterial growth?. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2015, 68, 870-871.	1.0	10
53	Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients. BMC Cancer, 2014, 14, 954.	2.6	9
54	Long-term impact of lipofilling in hybrid breast reconstruction: retrospective analysis of two cohorts. European Journal of Plastic Surgery, 2020, 43, 257-268.	0.6	9

#	Article	IF	CITATIONS
55	Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93. Annals of Oncology, 2007, 18, 1177-1184.	1.2	8
56	Preclinical validation of a novel compound targeting p70S6 kinase in breast cancer. Aging, 2016, 8, 958-977.	3.1	8
57	Elaboration of a nomogram to predict nonsentinel node status in breast cancer patients with positive sentinel node, intraoperatively assessed with one step nucleic amplification: Retrospective and validation phase. Journal of Experimental and Clinical Cancer Research, 2016, 35, 193.	8.6	7
58	Toxicity and cosmesis following partial breast irradiation consisting ofÂ40ÂGy in 10 daily fractions. Breast, 2013, 22, 744-747.	2.2	6
59	Ten daily fractions for partial breast irradiation. Long-term results of a prospective phase II trial. Breast Journal, 2019, 25, 243-249.	1.0	6
60	An efficient method for the correction of iatrogenic symmastia: A case series. Annals of Medicine and Surgery, 2018, 29, 14-18.	1.1	5
61	p27kip1 expression limits H-Ras-driven transformation and tumorigenesis by both canonical and non-canonical mechanisms. Oncotarget, 2016, 7, 64560-64574.	1.8	5
62	Seven fractions to deliver partial breast irradiation: the toxicity is Low. Radiation Oncology, 2017, 12, 86.	2.7	4
63	Suspected breast implant rupture: our experience, recommendations on its management and a proposal for a model of informed consent. European Journal of Plastic Surgery, 2020, 43, 569-576.	0.6	4
64	Epirubicin and Docetaxel as Neoadjuvant Treatment of Locally Advanced Breast Cancer: A Phase II Study. Tumori, 2010, 96, 229-233.	1.1	3
65	Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies. Radiology and Oncology, 2013, 47, 57-62.	1.7	2
66	In Regard to Hepel and Wazer. International Journal of Radiation Oncology Biology Physics, 2015, 92, 953-954.	0.8	2
67	In Regard to Polgar et al. International Journal of Radiation Oncology Biology Physics, 2021, 110, 905-907.	0.8	2
68	Epirubicin and docetaxel as neoadjuvant treatment of locally advanced breast cancer: a phase II study. Tumori, 2010, 96, 229-33.	1.1	2
69	KIR-HLA Functional Repertoire Influences Trastuzumab Efficiency in Patients With HER2-Positive Breast Cancer. Frontiers in Immunology, 2021, 12, 791958.	4.8	2
70	High-Dose Epirubicin in Locally Advanced Operable Noninflammatory Breast Cancer: A Feasibility Trial. Tumori, 1997, 83, 656-660.	1.1	0
71	Increased tissue stiffness during mammography may contribute to carcinogenesis. International Journal of Surgery, 2007, 5, 213.	2.7	Ο
72	In Reply to Park etÂal. International Journal of Radiation Oncology Biology Physics, 2016, 96, 707-708.	0.8	0

#	Article	IF	CITATIONS
73	A Risk-Adapted Approach to Breast Radiation Using Targeted Intraoperative Radiotherapy (TARGIT). , 2016, , 327-346.		0